FINHUB Insights

Pfizer Q3 FY25: where the revenue came from and where it went

The whole income statement of Pfizer for this quarter, as one diagram: what earned the revenue, and what it went on.

Period
Jun 30 – Sep 28, 2025
Reported
Nov 4, 2025 10-Q accession 0000078003-25-000150

Revenue$16.7B −6% year over year
Gross profit$12.5B 75% margin
Operating profit−$3.6B −21% margin
Net profit$3.5B 21% margin

Net profit is larger than what operations earned, because the statement adds $7.1B below it, under Tax benefit and other.

100% free

It's free. All of it.

A free account opens every diagram. We send one link to confirm your address, and that is the whole of it.

Already have an account? Sign in

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 28, 2025).
ItemValueShare of revenueYear over year
Revenue 16.7 100% −6%
US 10.7 64% −11%
Developed markets 3.7 22% +8%
International emerging 2.3 14% +2%
Cost of revenue−4.225%
Gross profit12.575% margin+5pp
SG&A−3.219%+1pp
Other−12.877%+0pp
Operating profit−3.6−21% margin+0pp
Tax benefit and other7.1
Net profit3.5 21% margin−4pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

359 of 418 companies, most recently reported first